<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Telaprevir</strong></td></tr><tr><th>Accession Number</th><td><strong>DB05521</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Telaprevir (VX-950) is a highly selective and potent inhibitor of the <span class="caps">HCV</span> NS3-4A serine protease. It is a member of a class of antiviral drugs known as protease inhibitors and is the first hepatitis C drug that has demonstrated activity in patients who have failed prior therapy. On April 28, 2011, the <span class="caps">FDA</span> Antiviral Drugs Advisory Committee voted 18-0 to recommend approval telaprevir for people with genotype 1 chronic hepatitis C and was approved in the U.S. in May, 2011.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB05521/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB05521/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05521.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05521.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05521.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05521.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05521.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB05521">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>MP-424</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Incivek</td><td> Johnson &amp; Johnson</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>402957-28-2</td></tr><tr><th>Weight</th><td>Average: 679.8493<br>Monoisotopic: 679.405732463</td></tr><tr><th>Chemical Formula</th><td>C<sub>36</sub>H<sub>53</sub>N<sub>7</sub>O<sub>6</sub></td></tr><tr><th>InChI Key</th><td>BBAWEDCPNXPBQM-GDEBMMAJSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3S)-3-{[(1S,3aR,6aS)-2-[(2S)-2-[(2S)-2-cyclohexyl-2-(pyrazin-2-ylformamido)acetamido]-3,3-dimethylbutanoyl]-octahydrocyclopenta[c]pyrrol-1-yl]formamido}-N-cyclopropyl-2-oxohexanamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Hybrid Peptides</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids and Derivatives; Alpha Amino Acid Amides; Pyrazinecarboxamides; Pyrrolidinecarboxamides; Tertiary Carboxylic Acid Amides; Secondary Carboxylic Acid Amides; Tertiary Amines; Ketones; Cyclic Alcohols and Derivatives; Enolates; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; alpha-amino acid amide; alpha-amino acid or derivative; pyrazine carboxylic acid or derivative; pyrazinecarboxamide; pyrrolidine-2-carboxamide; pyrrolidine carboxylic acid or derivative; pyrazine; pyrrolidine; cyclic alcohol; tertiary carboxylic acid amide; carboxamide group; secondary carboxylic acid amide; tertiary amine; ketone; polyamine; enolate; carboxylic acid; amine; carbonyl group; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treating chronic hepatitis C virus (genotype 1) infection in patients with compensated liver (due to liver diseases like cirrhosis) that are treatment naive or have failed therapy with interferons (either null or partial responders and treatment relapsers). </td></tr><tr><th>Pharmacodynamics</th><td>Telaprevir is a direct-acting antiviral agent (DAA) against the hepatitis C virus. In a biochemical assay, telaprevir inhibited the proteolytic activity of the recombinant HCV NS3 protease domain with an IC50 value of 10 nM.</td></tr><tr><th>Mechanism of action</th><td>Telaprevir is an inhibitor of the HCV NS3/4A serine protease, necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS4A, NS4B, NS5A and NS5B proteins and essential for viral replication. It belongs to the chemical class of alpha-ketoamids and binds to NS3/4A in a covalent but reversible manner. </td></tr><tr><th>Absorption</th><td>Telaprevir is orally available, most likely absorbed in the small intestine, with no evidence for absorption in the colon. Maximum plasma concentrations after a single dose of telaprevir are generally achieved after 4 to 5 hours. In vitro studies performed with human Caco-2 cells indicated that telaprevir is a substrate of P-glycoprotein (P-gp). Exposure to telaprevir is higher during co-administration of peginterferon alfa and ribavirin than after administration of telaprevir alone. Dissolution of telaprevir is not dependent by pH. </td></tr><tr><th>Volume of distribution</th><td><p>Apparent volume of distribution (Vd/F) = 252 L. This large volume of distribution suggests extensive penetration into tissues.</p></td></tr><tr><th>Protein binding</th><td>59% to 76% and binds to alpha 1-acid glycoprotein and albumin in a concentration dependent manner. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Telaprevir is extensively metabolized in the liver, involving hydrolysis, oxidation, and reduction. Multiple metabolites were detected in feces, plasma, and urine. After repeated-oral administration, the R-diastereomer of telaprevir (30-fold less active), pyrazinoic acid, and a metabolite that underwent reduction at the &#945;-ketoamide bond of telaprevir (not active) were found to be the predominant metabolites of telaprevir. In vitro studies using recombinant human cytochrome P450 (CYP) isoforms indicated that CYP3A4 was the major CYP isoform responsible for telaprevir metabolism. However, non-CYP mediated metabolism likely plays a role after multiple dosing of telaprevir.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Telaprevir</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00993">Pyrazinoic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1016">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Following administration of a single oral dose of 750 mg 14C-telaprevir in healthy subjects, 90% of total radioactivity was recovered in feces, urine and expired air within 96 hours post-dose. The median recovery of the administered radioactive dose was approximately 82% in the feces, 9% in exhaled air and 1% in urine. The contribution of unchanged 14C-telaprevir and the R-diastereomer of telaprevir towards total radioactivity recovered in feces was 31.9% and 18.8%, respectively.</td></tr><tr><th>Half life</th><td>The mean elimination half-life after single-dose oral administration of telaprevir 750 mg typically ranged from about 4.0 to 4.7 hours. At steady state, the effective half-life is about 9 to 11 hours.</td></tr><tr><th>Clearance</th><td><p>After oral administration, the apparent total clearance (Cl/F) was estimated to be 32.4 L/h with an inter-individual variability of 27.2%.</p></td></tr><tr><th>Toxicity</th><td>The highest documented dose administered is 1875 mg every 8 hours for 4 days in healthy subjects with telaprevir alone. In that study, the following common adverse events were reported more frequently with the 1875 mg q8h regimen compared to the 750 mg q8h regimen: nausea, headache, diarrhea, decreased appetite, dysgeusia, and vomiting. The two most common adverse events that caused the discontinuation of treatment are anemia and rash. </td></tr><tr><th>Affected organisms</th><td><ul><li>Hepatitis C virus, RSV and other RNA/DNA viruses</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9547</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7982</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8567</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.9355</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8879</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8245</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6612</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7632</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6961</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.5969</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7431</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5866</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.8926</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8476</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7536
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8622
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9954
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6980 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9894
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6931
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, film coated</td><td>Oral</td><td>375mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00346">Alfuzosin</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Telaprevir inhibits systemic metabolism of alprazolam and dose adjustment may be necessary. </td></tr><tr><td><a href="/drugs/DB00381">Amlodipine</a></td><td>Telaprevir inhibits the metabolism of amlodipine and concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01013">Clobetasol propionate</a></td><td>Corticosteroids such as clobetasol may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects. </td></tr><tr><td><a href="/drugs/DB00838">Clocortolone</a></td><td>Corticosteroids such as clocortolone may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of Corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Telaprevir is a substrate of p-glycoprotein and thus increases the AUC and Cmax of digoxin. This indicates an increased absorption of digoxin. Lowest dose of digoxin should be used first and levels be closely monitored. 
</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Inducers of CYP3A enzymes will decrease telaprevir levels. </td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Telaprevir decreases Cmax, Cmin, and AUC of escitalopram however the mechanism of this interaction is unknown. Concomitant therapy may call for dose adjustment. </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Telaprevir, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor telaprevir therapy closely.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Strong CYP3A4 inhibitors increase exposure of telaprevir. </td></tr><tr><td><a href="/drugs/DB08827">Lomitapide</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Telaprevir decreases exposure of methane by 30% however opioid withdrawal was not observed in patients. </td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Telaprevir increases AUC and Cmax of oral midazolam by approximately 9-fold and 3-fold respectively. </td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB06817">Raltegravir</a></td><td>Telaprevir increases the exposure of raltegravir by up to 31%  but this interaction is considered as not clinically relevant. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Strong CYP3A4 inducers will decrease levels of telaprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>St. John's wort is a CYP3A4 inducer which will decrease levels of telaprevir.</li></ul></td></tr></tbody></table>